Good morning, everyone, and thank you for dialing in to the Q2 2026 earnings call for the Vitrolife AB Group. I would like to start with three key highlights in the quarter. We delivered record revenue of 358 MSEK in consumables, which represents 15% organic growth in our Americas region, a net income of 129 MSEK, and an EPS of 0.956. We also launched EmbryoCath and EmbryoViewer Pro. So for the first time, we can compete in the embryo transfer segment. EmbryoViewer Pro, which we recently showcased at the ESHRE Congress, is an advanced software program for our EmbryoScope time-lapse system.
I will now move us on, and I would like to provide you with an overview of the market in each of our regions, starting with EMEA. European IVF cycle activities appear to be at normal levels. However, in the region, the Middle East crisis is impacting IVF cycles significantly. We do not. In the Vitrolife AB group, we do not see Middle East distributors restocking at this time. In fact, the airspace has been regularly closed. So even shipping goods into the region is a challenge.
In the APAC region, which I recently visited myself, we see that IVF cycles in China are declining year over year. This trend is expected to continue based on population demographics. Southeast Asia within the APAC region is growing as access increases in Japan and Korea. The combined markets are growing in the low single digits. Although the birth rate in Korea has rebounded significantly in 2026, with total fertility increasing above 0.9 for the first time in many years. So one could reasonably expect a pickup in cycles in South Korea. In the Americas region, if we look at the US, cycle activity was very slow at the start of Q2. Specifically in April and May. But it started to pick up in the month of June. There were wide variations between the US states, with wealthier areas like Massachusetts, New York, and Southern California performing stronger. In South America, we see an increased presence of low-cost generic competitors in genetics. Cycle activity remains robust in the Americas region, specifically within South America. Okay, so moving on to look at the performance in our largest region, EMEA, which accounts for 37% of our global revenue, as is evidenced from our donut chart here on the right-hand side of the slide. We delivered 1% organic growth in local currencies, excluding the exited business of NIDA and GDPS. Western Europe remained strong. However, IVF cycles, as I've just mentioned, are significantly down in the Middle East, and this weighed on the regional performance. Consumables grew 4% in local currencies, with Europe performing well and the Middle East behind prior year. Technologies increased 3% in local currencies with installs in Europe offset by low capital demand in the Middle East. And we are also seeing positive trends month after month in the consumable revenue stream from our EmbryoScope systems. Genetics decreased by 3% with the Middle East volumes down substantially. We've been focusing on driving margin improvement in all regions, so it's very pleasing to see the positive trend in our gross margin. So if you just look at the chart for the first time, you won't have seen this in previous slides that I've presented, but we have added the gross margin trend. And what you see here is a two percentage point improvement in gross margin, primarily driven in the case of EMEA by the exit of non-core assets and GDPX, and also our operational efficiency program, which we have been focusing on across the Vitrolife AB group.
We will now move on and look at the Americas. In the Americas region, we delivered 1% organic growth in local currencies. The share of revenue coming from Americas now stands at 34%. As you can see here in the donut on the right-hand side, North America performed well across the portfolio. You know that this is one of our key focus markets. We have been doubling down here for a couple of years now. South America's exit from low-profit genetic accounts reduced top-line growth, but it improved regional profitability. Consumables increased by 15% in local currencies, with significant gains in media in North and South America. We are delighted with these wins because we've really doubled down to take share here, and I want to thank my team for their huge efforts in bringing these wins over the line. Time-lapse decreased by 9% due to a large capital deal with a clinic chain in the same quarter last year, which most of you will likely remember. South America had a very strong capital sales quarter. As we increase our focus on EmbryoScope, we are both increasing the penetration of the capital systems and the utilization of those EmbryoScope units, while Genetics decreased by 3% with continued growth in our key focus market of North America, offset by the exit of low profit accounts in South America. This is a strategic decision as we do not want to compete in low-profit segments. We are a premium service, differentiated company with best-in-class technology and genetics, and we will not follow low-price generic competitors. A 3.6 percentage point improvement in our gross margin. And this is really down to our increased focus on consumables in the Americas. Again, this is a strategic decision to focus on this area. And we believe we have further opportunities in consumables and in technologies, particularly in South America, but also in North America. Okay, we will now finally move on to the APAC region, where we had a decline of 1% organic growth in local currencies. APAC now accounts for 29% of our global revenue. I am delighted to report that Japan delivered strong growth, our best in several years. In fact, we continue to expand our share across the portfolio in Southeast Asia. However, as I have mentioned, demand in China slowed further as the quarter progressed. Sales in consumables decreased by 5% with a strong performance in Southeast Asia and Japan, offset by weak demand in China. Technologies increased by 6%, primarily driven by capital sales in Japan. This is particularly pleasing to see because Japan is a highly penetrated market for EmbryoScope. A big call out to our Japan team for the really nice job that they have done. Their genetics increased by 2% across the region, so slightly above the regional growth rate for APAC at present, a 1.4 percentage point increase in gross margin driven by price increases and operational efficiency. The team on the ground has done a really nice job here, so driving price gains in a very competitive market is not an easy thing to do. And I think the Vitrolife AB group APAC team have done a really nice job here.
Okay, so I'll move on to the final slide, my final slide, at least before I hand over to Pär.
As you know very well by now, the Vitrolife AB group has a mission to be the leading global partner in reproductive health, striving for better outcomes for patients. We focus on three key areas to get to that coveted number one spot. They are growth, innovation and operational excellence. So how are we doing? Are we advancing in these key areas? So when it comes to growth, we are driving profitable growth through improved market and customer segmentation. I believe you can really see this in this quarter. We are doubling down on the markets, on the areas of the portfolio, and on the customers where Vitrolife AB group can drive profitable growth. We are gaining share in consumables. This represents 15% organic growth in the Americas for media. That is well above the growth rates there. And we are increasing the penetration and utilization of EmbryoScope. We are also building out our platform solution with the combination of EmbryoScope and eWitness in relation to innovation. We are not just talking about innovation. We have delivered. We launched EmbryoCath and EmbryoViewer Pro, which we showcased at ESHRE. However, we also have more launches planned in the coming quarters, and I really want to thank our R&D and innovation teams for the work that they have been doing there. We are also advancing the efficiency of IVF clinics, partnering with our customers, and driving the use of AI in embryo selection. When it comes to operational excellence, we continue to invest in digital capabilities to improve the customer journey and our connectivity with clinics. We have taken actions, and you can see this in our quarterly results. We have taken actions to optimize our cost base across operations and back office. So we are doing what we said we would do when it comes to our restructuring program. So I would say in summary, we are advancing our mission and we are doing it in a profitable, sustainable way. I will now hand you over to Pär, who will take you through the key financials.